Paper40144682
Future perspectives on immunotherapy for hepatocellular carcinoma.
Chan LL and 1 other. Ther Adv Med Oncol, 2025. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Future perspectives on immunotherapy for hepatocellular carcinoma. Papers, record 40144682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40144682
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References116
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41647284 | Neoadjuvant immunotherapy for early-stage hepatocellular carcinoma: the arts and science. | ESMO Gastrointest Oncol | 2023 | https://conductscience.org/library/papers/41647284 | PubMed |
| 2 | 39325464 | Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma. | JAMA Oncol | 2024 | https://conductscience.org/library/papers/39325464 | PubMed |
| 3 | 22004366 | Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. | J Gastroenterol Hepatol | 2012 | https://conductscience.org/library/papers/22004366 | PubMed |
| 4 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 5 | 33791252 | Anti-PD-1 Immunotherapy Improves the Efficacy of Hepatic Artery Infusion Chemotherapy in Advanced Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2021 | https://conductscience.org/library/papers/33791252 | PubMed |
| 6 | 31550417 | Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? | Am J Transplant | 2020 | https://conductscience.org/library/papers/31550417 | PubMed |
| 7 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 8 | 38086815 | Therapeutic cancer vaccines: advancements, challenges, and prospects. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/38086815 | PubMed |
| 9 | 32104669 | The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2020 | https://conductscience.org/library/papers/32104669 | PubMed |
| 10 | 38382875 | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. | Ann Oncol | 2024 | https://conductscience.org/library/papers/38382875 | PubMed |
| 11 | 36894804 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. | J Gastroenterol | 2023 | https://conductscience.org/library/papers/36894804 | PubMed |
| 12 | 32735779 | Engineering CAR-T Cells for Next-Generation Cancer Therapy. | Cancer Cell | 2020 | https://conductscience.org/library/papers/32735779 | PubMed |
| 13 | 34914889 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/34914889 | PubMed |
| 14 | 32127929 | Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. | J Cancer | 2020 | https://conductscience.org/library/papers/32127929 | PubMed |
| 15 | 36856617 | Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. | N Engl J Med | 2023 | https://conductscience.org/library/papers/36856617 | PubMed |
| 16 | 39147893 | Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions. | Nat Rev Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/39147893 | PubMed |
| 17 | 12547409 | Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. | J Hepatol | 2003 | https://conductscience.org/library/papers/12547409 | PubMed |
| 18 | 29040999 | Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis. | Dig Dis | 2017 | https://conductscience.org/library/papers/29040999 | PubMed |
| 19 | 33419761 | Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33419761 | PubMed |
| 20 | 36108891 | Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. | Int J Radiat Oncol Biol Phys | 2023 | https://conductscience.org/library/papers/36108891 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42566079 | Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies. | Med Oncol | 2026 | https://conductscience.org/library/papers/42566079 | PubMed |
| 42346124 | Immunotherapy and Hepatocellular Carcinoma: From Tumor-Immune Cell Interactions to Rational Therapeutic Strategies. | Cells | 2026 | https://conductscience.org/library/papers/42346124 | PubMed |
| 42255232 | Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system. | Front Oncol | 2026 | https://conductscience.org/library/papers/42255232 | PubMed |
| 42096002 | Knowledge mapping of ⁹⁰Y transarterial radioembolization combined with immunotherapy in hepatocellular carcinoma: a bibliometric analysis. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42096002 | PubMed |
| 41166641 | Clinical management of liver cancer patients with immune checkpoint inhibitors treatment. | Hepat Oncol | 2025 | https://conductscience.org/library/papers/41166641 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40144682
GET https://conductscience.org/api/papers/v1/40144682/references?page=2